Goldman Sachs Initiates Coverage of DexCom with Buy Rating

On May 30, 2025, Goldman Sachs began its coverage of DexCom (XTRA:DC4) with a Buy recommendation.

Analyst Price Forecast Indicates Potential Gain

The average one-year price target for DexCom is €90.06 per share, as of May 7, 2025. Predictions vary from a low of €73.74 to a high of €107.51, suggesting a potential upside of 20.48% from its last closing price of €74.75 per share.

Projected Revenue and Earnings

Annual revenue for DexCom is projected at €5.231 billion, marking a 26.11% increase. The expected non-GAAP EPS is €2.20.

Fund Sentiment Analysis

A total of 1,818 funds or institutions currently hold positions in DexCom, reflecting a decrease of 71 fund owners or 3.76% from the previous quarter. The average portfolio weight for all funds in DC4 is 0.24%, up by 1.34%. Institutional shares increased by 2.16% over the last three months to 436.857 million shares.

Shareholder Activity

Baillie Gifford owns 14.18 million shares, representing 3.62% of the company. This is a decrease from 14.613 million shares, down 3.05%, with a 63.38% reduction in portfolio allocation in DC4 last quarter.

The Vanguard Total Stock Market Index Fund Investor Shares holds 12.36 million shares (3.15% ownership) and increased its holdings slightly from 12.259 million shares by 0.81%. Portfolio allocation in DC4 decreased by 7.65%.

Capital Research Global Investors holds 12.037 million shares for 3.07% ownership, down from 14.372 million shares, marking a 19.40% decrease and a 22.22% reduction in portfolio allocation.

The Vanguard 500 Index Fund Investor Shares retains 10.858 million shares (2.77% ownership), an increase from 10.573 million shares by 2.62%. Portfolio allocation in DC4 was reduced by 7.92%.

Jennison Associates increased its holdings from 7.644 million shares to 10.523 million shares (2.68% ownership), but reduced its portfolio allocation in DC4 by 25.84%.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.